Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
about
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsEpigenetics of cervical cancer. An overview and therapeutic perspectivesGut Microbiota Imbalance and Base Excision Repair Dynamics in Colon CancerThe clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancerThe implications of heterogeneous DNA methylation for the accurate quantification of methylationA distinct epigenetic signature at targets of a leukemia protein.Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylationActivity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.Current data and strategy in glioblastoma multiformeChemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylationO6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples.Epigenetic changes in prostate cancer: implication for diagnosis and treatment.Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiationO(6)-methylguanine-DNA methyltransferase in equine sarcoids: molecular and epigenetic analysis.MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.Epigenetic gene silencing in cancer: the DNA hypermethylome.DNA methylation profile distinguishes clear cell sarcoma of the kidney from other pediatric renal tumorsRole of MGMT as biomarker in colorectal cancer.Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile.The role of O(6)-methylguanine-DNA methyltransferase polymorphisms in colorectal cancer susceptibility: a meta analysis.Aberrant DNA methylation and prostate cancer.Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomasMutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker designSmall cell lung cancer: will recent progress lead to improved outcomes?DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapyNovel therapeutic approaches for small cell lung cancer: the future has arrivedTelomerase: a potential therapeutic target for cancer.Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis.Applying whole-genome studies of epigenetic regulation to study human disease.DNA repair gene variants in relation to overall cancer risk: a population-based studyMechanisms of chemoresistance to alkylating agents in malignant glioma.Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.Bendamustine as a model for the activity of alkylating agents.Correlation of MLH1 and MGMT methylation levels between peripheral blood leukocytes and colorectal tissue DNA samples in colorectal cancer patients.DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A.
P2860
Q24607903-844BD4A4-6343-46E1-9F0D-B3420BB55093Q24812104-CFD465D8-40ED-4E89-B9B0-1A80E5ECD99DQ26740627-68E3D4C8-8C20-49E7-9512-B92189B63CB1Q26766285-24DD7BB5-C1F2-4910-8906-8228863EF85DQ28254096-C7005B3F-7C78-4785-BD14-A2B5697AABC7Q33271210-AB1B3217-441D-49E2-B5DF-1836237C3757Q33383951-C2A2EE84-4842-44A5-91B6-36F954A4BA63Q33412380-CBE69856-C423-4153-BCD7-E4CBAC04493FQ33417537-F15D3C68-7C0C-4DC5-A7CC-2DFA02C8DC71Q33527073-E332BF01-A535-438B-A3D5-B0B08613D396Q33575712-24E8E77A-868E-48BF-A419-C414CC8CAA7CQ33804528-3B3F388F-B6D7-4F27-9835-7D884053C75DQ34014559-F282E5D6-CF50-47F8-9388-37AE38442470Q34385658-4E9F0BDB-20A4-4183-935B-511AAB765028Q34405013-D48E6477-760F-470B-95A0-99E41ED28446Q34472476-A4FAF03B-6BE5-45ED-A240-919ED19A3547Q34507966-33D72E10-D6F8-4427-8195-8760CFCCB2E1Q34646556-54DCB458-A155-4C44-9D67-31559D5D5207Q34701105-915C928D-DCEF-4F5D-9A32-588896DAF0FEQ34706115-F3569B21-4725-4F5E-B979-B83222A9E164Q35096197-817242C7-246F-4139-9951-2D7C5E09BFE4Q35173608-E4D12A1A-361F-4F52-88FF-62ABDB9CAAAFQ35560819-D267CE12-3CA0-4E24-9834-6280FE0E59E9Q35598151-7279A36E-7D97-4F0E-8865-8258FC3596F9Q35790060-69CB7533-7F7C-48F4-A856-5722236B7AACQ35795835-E3139027-5270-49BF-B658-3CFD96A53217Q35836257-30C9B8AE-41AF-40D7-B542-A4A40E3646F3Q36012002-E9B7CC0D-E1AA-46EC-BBDB-23F974533AF7Q36084288-AC74E3D6-B163-4764-831E-59EA9435166DQ36158693-D1CF741E-69FF-4CB2-810B-7E52C9C19565Q36261945-DEEA8FE4-E446-4F07-A7CA-D0F20321D676Q36485572-09FD313F-9B69-497E-BF0A-43CA31E2A9BDQ36499747-9977950D-4BE9-4663-99C4-0F588EB2E64FQ36726010-B93F3C15-A136-4F74-A6FB-AED1BB3A8C36Q36801625-AEDAE295-4152-437A-B5AA-D107FBDC673CQ36964700-F15AD5F9-3EBB-419A-8B9A-7BFA85972AA2Q37031517-DACE0905-69EC-42CF-B63D-44D5A3697D2EQ37179377-24612E24-3E59-4E4D-8FD3-335D0663FE17Q37269557-933D3450-DEEF-4D1B-B3A6-25010B33D248Q37273862-7BB7D204-B4D3-4981-A628-046E2B71AD17
P2860
Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Generating mutations but provi ...... yltransferase in human cancer.
@ast
Generating mutations but provi ...... yltransferase in human cancer.
@en
Generating mutations but provi ...... yltransferase in human cancer.
@nl
type
label
Generating mutations but provi ...... yltransferase in human cancer.
@ast
Generating mutations but provi ...... yltransferase in human cancer.
@en
Generating mutations but provi ...... yltransferase in human cancer.
@nl
prefLabel
Generating mutations but provi ...... yltransferase in human cancer.
@ast
Generating mutations but provi ...... yltransferase in human cancer.
@en
Generating mutations but provi ...... yltransferase in human cancer.
@nl
P2860
P356
P1433
P1476
Generating mutations but provi ...... yltransferase in human cancer.
@en
P2093
James G Herman
P2860
P2888
P356
10.1038/SJ.ONC.1207316
P407
P577
2004-01-01T00:00:00Z
P5875
P6179
1038974145